公司诉讼事件 - 美国新泽西地方法院受理针对UroGen Pharma的集体诉讼案 代表2023年7月27日至2025年5月15日期间购入公司证券的投资者 [1] - 诉讼指控公司在整个报告期内作出虚假或误导性陈述 包括未披露UGN-102临床试验设计缺陷导致难以证明药效归因性 [3] - FDA在2025年5月16日公开文件指出ENVISION研究缺乏对照组 使主要疗效终点数据难以解释 当日股价暴跌26% [4] - 2025年5月21日肿瘤药物咨询委员会投票反对UGN-102新药申请 认为风险收益比不利 当日股价再跌45% [5] 产品研发情况 - 公司专注于 specialty cancers 领域解决方案开发与商业化 核心管线产品UGN-102为治疗低级别中危非肌层浸润性膀胱癌的膀胱内溶液 [2] - 被指控忽视FDA多次关于研究设计的警告 未采用随机对照试验方案 导致新药申请存在重大否决风险 [3] 投资者参与方式 - 投资者可在2025年7月28日前向法院申请成为首席原告 [1] - 律所Bragar Eagel & Squire提供专项法律咨询通道 包括电话与邮件联系方式 [6][10]

JPMorgan Chase CEO Jamie Dimon on Tuesday said that while the U.S. economy has stayed strong through the second quarter of this year, there remain potential stumbling blocks to the economic outlook. Dimon said that the "U.S. economy has remained resilient" and noted that while there are potential boosts coming from the enactment of Republicans' tax and spending package, other headwinds could dampen the economic outlook going forward."The finalization of tax reform and potential deregulation are positive for ...

股价表现 - Autodesk最新收盘价下跌1.9%至288.96美元，表现逊于标普500指数（下跌0.4%）和道琼斯指数（下跌0.98%），但优于纳斯达克指数（上涨0.18%）[1] - 过去一段时间公司股价累计下跌1.59%，落后于计算机与科技行业（上涨6.34%）和标普500指数（上涨4.97%）[1] 业绩预期 - 公司即将公布的季度EPS预计为2.44美元，同比增长13.49%，营收预计为17.3亿美元，同比增长14.65%[2] - 全年EPS预计为9.64美元（同比增长13.81%），营收预计为69.7亿美元（同比增长13.67%）[3] - 分析师近期上调EPS共识预期0.12%，显示对业务前景的乐观情绪[3][5] 估值指标 - 公司当前远期市盈率为30.56，高于行业平均的28.28[6] - PEG比率为1.94，低于互联网软件行业平均的2.18[6] 行业地位 - 公司所属的互联网软件行业在Zacks行业排名中位列第64，处于前26%分位[7] - 该行业属于计算机与科技板块，研究显示排名前50%的行业表现优于后50%[7]

Amerigo Resources (ARREF) ended the recent trading session at $1.67, demonstrating a +1.03% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.4%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, added 0.18%. The copper and molybdenum mining company's stock has climbed by 17.86% in the past month, exceeding the Basic Materials sector's gain of 2.16% and the S&P 500's gain of 4.97%.The investment community will be closely monito ...

In the latest close session, Humacyte, Inc. (HUMA) was down 7.69% at $2.28. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, added 0.18%. The company's shares have seen an increase of 2.49% over the last month, surpassing the Medical sector's loss of 1.56% and falling behind the S&P 500's gain of 4.97%.The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report ...

BigBear.ai Holdings, Inc. (BBAI) closed the most recent trading day at $7.10, moving +2.6% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.4% for the day. Elsewhere, the Dow saw a downswing of 0.98%, while the tech-heavy Nasdaq appreciated by 0.18%. Prior to today's trading, shares of the company had gained 67.15% outpaced the Computer and Technology sector's gain of 6.34% and the S&P 500's gain of 4.97%.Market participants will be closely following the financ ...

In the latest trading session, Hershey (HSY) closed at $162.91, marking a -1.21% move from the previous day. This change lagged the S&P 500's daily loss of 0.4%. Meanwhile, the Dow experienced a drop of 0.98%, and the technology-dominated Nasdaq saw an increase of 0.18%. Shares of the chocolate bar and candy maker witnessed a loss of 3.23% over the previous month, trailing the performance of the Consumer Staples sector with its loss of 1.24%, and the S&P 500's gain of 4.97%.Investors will be eagerly watchin ...

In the latest trading session, KLA (KLAC) closed at $936.53, marking a +1.59% move from the previous day. This move outpaced the S&P 500's daily loss of 0.4%. Elsewhere, the Dow saw a downswing of 0.98%, while the tech-heavy Nasdaq appreciated by 0.18%. Prior to today's trading, shares of the maker of equipment for manufacturing semiconductors had gained 3.3% lagged the Computer and Technology sector's gain of 6.34% and the S&P 500's gain of 4.97%.The upcoming earnings release of KLA will be of great intere ...

MakeMyTrip (MMYT) ended the recent trading session at $93.01, demonstrating a +2.25% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.4% for the day. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq increased by 0.18%. Shares of the online travel company witnessed a loss of 9.83% over the previous month, trailing the performance of the Computer and Technology sector with its gain of 6.34%, and the S&P 500's ga ...

股价表现 - Ross Stores最新收盘价为127 59美元 单日跌幅2 73% 表现逊于标普500指数0 4%的跌幅 道琼斯指数下跌0 98% 纳斯达克指数上涨0 18% [1] - 过去一个月公司股价微涨0 02% 同期零售批发行业上涨4 14% 标普500指数上涨4 97% [1] 财务预期 - 公司即将公布的季度EPS预计为1 54美元 同比下降3 14% 营收预计55 3亿美元 同比增长4 68% [2] - 全年EPS预期6 23美元 同比下降1 42% 营收预期219 9亿美元 同比增长4 07% [3] - 过去30天内分析师对EPS预期上调0 3% [5] 估值指标 - 公司远期市盈率21 04倍 低于行业平均的21 39倍 [6] - PEG比率2 51倍 低于折扣零售行业平均的2 81倍 [7] 行业排名 - 折扣零售行业在Zacks行业排名中位列155 处于所有250个行业中的后38% [7] - 行业排名前50%的组别表现通常比后50%高出2倍 [8] 分析师评级 - 公司当前Zacks评级为4级(卖出) 该评级系统历史数据显示1级(强力买入)股票年均回报率达25% [5]